- 江苏省人感染H7N9禽流感中医...
- 养阴清热法治疗老年人失眠疗效评...
- 中医药治疗失眠症的方法与思路研...
- 中医治疗失眠症的临床研究概要
- 中医人当如何提振"精气神"
- 不忘脾胃是养生首要 中医专家教...
- 冬季荸荠滋润吃
- 参黄冲剂对衰老患者NO和SOD...
- 参黄冲剂对衰老患者P16基因m...
- 参黄冲剂延缓衰老作用的评价及内...
- 参黄冲剂对衰老患者抗氧化作用及...
- 建立健全附属医院临床带教队伍管...
- 冠心平对冠心病心绞痛患者血脂和...
- 胡铁城教授治疗老年疑难杂症病案...
- 现代临床中医的未来----中国...
- 中医治疗失眠的研究进展
- 李时珍防治老年病思想论要
- 源于中医 衷中参西 继承发展 ...
- 谫论心衰的中医证治思路
- 参黄冲剂对衰老患者P16基因m...
- 参黄冲剂延缓衰老作用的评价及内...
- 李七一教授中医治疗心血管疑难病...
- 中医理论与冠心病患者的健康生活...
- 王国强副部长提出了七个“把握
- 核事故防护知识要点
- 中医养生的策略
- 老年人食疗保健
- 健身养生八法
- 八位名医养生法盘点
- 老年人食疗保健
- 道家修养
- 情绪低落的时候如何办
- 胃 疾 随 咏
- 用机制促进名中医培养
- 中医之道恩
- 自主神经功能障碍(晕厥)的辨治...
- 血管性痴呆的辨治与验案
- 高血压脑病的辨治与验案
- 蛛网膜下腔出血的辨治与验案
- 脑出血的辨治与验案
- 脑梗死的辨治与验案
- 特发性起立性低血压的辨治与验案
- 慢性心力衰的辨治与验案
- 肥厚型心肌病的辨治与验案
- 扩张型性心肌病的辨治与验案
- 心包炎的辨治与验案
- 病毒性心肌炎的辨治与验案
- 风湿性心瓣膜病(二尖瓣狭窄)
- 急性心肌梗塞辨治与验案
- 心绞痛的辨治与验案
- 高血压的辨治与验案
- 构建卓越中医师培养新模式
- 用机制促进名中医培养
- 中医是打开中华文明宝库的钥匙
- 中医药应遵循自身规律科学发展
- 周仲瑛教授治疗疑难杂证用药经验...
- 中医理论与冠心病患者的健康生活...
- 按中医药人才成长规律施教
- 用机制促进名中医培养
- 通心络胶囊干预载脂蛋白E基因敲...
- ApoE基因多态性与冠状动脉粥...
- 冠心病(胸痹)辨证分型研究的历...
- 高温中暑预防知识要点
- 谫论中医院开展“师承培养”的模...
- 老年充血性心力衰竭的诊断与治疗
- 中医是打开中华文明宝库的钥匙
- 老年心律失常的诊断与治疗
- 老年急性心肌梗死的诊断与治疗
- 老年心绞痛的诊断与治疗
- 老年高血压病的诊断与治疗
- 老年循环系统的老化改变
- 源于中医 衷中参西 继承发展 ...
- 老人歌
- 五句话
- 通心络胶囊对不同载脂蛋白E基因冠状动脉粥样硬化性心脏病的影响
- 作者:韩旭|发布时间:2010-09-08|浏览量:1251次
通心络胶囊对不同载脂蛋白E基因冠状动脉
粥样硬化性心脏病的影响
韩 旭 李七一 赖仁胜 陈小虎 郭宏敏 赵惠
(江苏省中医院,江苏 南京 210029)
摘要 目的 应用基因测序技术观察通心络胶囊对不同载脂蛋白E(ApoE)基因冠状动脉粥样硬化性心脏病(CHD)的治疗效果,并探究ApoE基因多态性与治疗前后CHD中医证型证候积分、血脂水平的相关性,为中医辨证施治CHD提供分子生物学依据。方法 将118例CHD患者采用随机、对照、盲法试验设计,分为2组,对照组予单硝酸异山梨酯缓释片40 mg,每日1次口服;酒石酸美托洛尔片25 mg,每日2次口服;阿司匹林肠溶片25 mg, 每日1次口服;治疗组在对照组基础上同时予通心络胶囊3粒,每日3次口服。分别检测不同中医证型的ApoE基因多态性和治疗前后血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C),统计证候积分,比较通心络胶囊对不同ApoE等位基因、不同ApoE基因表型、不同证型CHD的中医证候积分和血脂水平的差异及疗效。结果 2组中医证候总积分治疗前后比较差异有统计学意义(P<0.05),治疗后中医证候总积分组间比较差异有统计学意义(P<0.05)。2组ε2、ε3、ε4 各等位基因治疗前治疗后自身比较,气阴两虚证、痰阻心脉证、心血瘀阻证均有统计学意义(P<0.05);治疗组ε4 与ε2、ε3比较,痰阻心脉证积分降低改善率最高(P<0.05),其他各基因表型间的气阴两虚证及心血瘀阻证改善率比较差异无统计学意义(P>0.05),治疗组ε4型改善痰阻心脉证疗效最好,优于ε2、ε3型;对照组各等位基因对于气阴两虚证、痰阻心脉证、心血瘀阻证积分改善率比较差异无统计学意义(P>0.05)。2组组内各不同基因表型调脂疗效比较,TC、LDL-C降低和HDL-C升高的改善率比较差异有统计学意义(P<0.05),TG降低的改善率比较差异无统计学意义(P>0.05),2组组间各相同基因表型间治疗前后改善率比较差异无统计学意义(P>0.05)。结论 通心络胶囊干预CHD疗效显著,对不同ApoE基因CHD的不同中医证型的疗效均具有影响,但对气阴两虚证、痰阻心脉证、心血瘀阻证具有明显疗效,尤以痰阻心脉证疗效最为显著;可有效降低TC、LDL-C和升高HDL-C。江苏省中医院老年科韩旭
关键词 载脂蛋白E类;基因多态现象, 遗传; 胶囊剂(中药); 胆固醇;冠状动脉疾病;辨证论治
中图分类号:R341; R543.3
Effect of Tongxinluo capsule on CHD of different apolipoprotein e(ApoE)gene
Abstract:
Objective:To observe the therapeutic effects of Tongxinluo capsule on CHD of different apolipoprotein e(ApoE)gene by applying the most advanced gene sequence testing technique, and to find the correlation between apolipoprotein e(ApoE)gene polymorphism and CHD Traditional Chinese Medicine pattern and blood-fat(before and after be treated),provding molecular biology envidences for CHD’ treatment to differentiation of symptoms and signs of TCM.
Methods: Make 118 CHD patients as the two groups by random、contrastion、blind trial.The control group were treated with isosorbide mononitrate 40 mg,once a day, metoprolol tartrate 25mg,twice a day, aspirin enteric-coated tablets 25mg,once a day.While the treatment group were treated on the base of control group with adding 3 Tongxinluo capsules,three times a day.Then respectively survey ApoEgene polymorphism of different tcm syndroms,indexes(pre and post treatment)of TC、TG、HDL-C and LDL-C,to get the statistic analysis on difference and effect(intervented by Tongxinluo capsule)of different apolipoprotein e(ApoE) allele、gene phenotype and CHD TCM pattern and level of blood-fat.
Results:Total integrals of both groups TCM pattern had statistical difference between before and after treatment(P<0.05).There was statistical difference of intergroup comparison after treatment(P<0.05). ε2、ε3、ε4 allele respectively compared with themselves between before and after treatment, deficiency of both qi and yin、coagulation of phlegm and heart blood stagnation syndromes of both groups were statistical different(P<0.05).ε4 allele compared with ε2、ε3 allele in treatment group,the decline-improvement rate of integral of coagulation of phlegm syndrome was best(P<0.05).There weren"t statistical differences of improvement of deficiency of both qi and yin and heart blood stagnation syndromes among all other gene phenotypes(P>0.05).Type ε4 in treatment group had the best effect of improving coagulation of phlegm syndrome,better than type ε2、ε3;while in control group,there were no significant differences of integral improvement of all the syndromes between each allele(P>0.05). For intergroup every different gene phenotype,comparison of effect of regulating lipid in both groups,differences were statistical significance in the decline of TC、LDL-C and increase of HDL-C(P<0.05),there wasn’t significant difference in the decline of TG(P>0.05).But for intergroup comparison of every same gene phenotype in both groups,differences between before and after treatment weren"t significant(P>0.05).
Conclusion: Herapeutic effect that Tongxinluo capsule interfere in is significant. Tongxinluo capsule can therapeuticly effect on different syndromes of TCM in different apolipoprotein e(ApoE) gene CHD,obviously on deficiency of both qi and yin、coagulation of phlegm and heart blood stagnation syndromes,but for coagulation of phlegm syndrome the effect is the best.There is obvious effect in the decline of TC、LDL-C and increase of HDL-C.
Key Words: Polymorphism of ApoE gene;Tongxinluo capsule;CHD;blood-fat; syndrome differ treatment
载脂蛋白E(apolipoprotein E,ApoE)基因多态性与冠状动脉粥样硬化性心脏病(Coronary heart disease,CHD)的发生、发展及严重程度密切相关,属于独立危险因子,具有一定的家族聚集性[1]。目前研究多侧重于ApoE基因多态性和CHD关联性以及对血脂代谢影响机制等领域。但是,中药制剂干预CHD反应存在较明显的个体差异,我们在前期工作的基础上,比较了ApoE基因多态性和CHD的不同中医证型对通心络胶囊干预反应的影响,结果如下。
1 资料与方法
1.1 一般资料 118例均为我院心脏科住院患者,采用随机、对照、盲法试验设计,中心分层、区组随机化方法分为2组,2组一般资料比较见表1。
表1 2组一般资料比较
|
治疗组(n=60) |
对照组(n=58) | |
性别[(男/女)(例)] |
42/18 |
37/21 | |
年龄(岁) |
38~70 |
41~72 | |
病程(年) |
0.5~9 |
1~8 | |
辨证分型 |
阴寒凝滞证[例(%)] |
7(11.67) |
6(10.34) |
痰阻心脉证[例(%)] |
16(26.67) |
13(22.41) | |
心血瘀阻证[例(%)] |
17(28.33) |
16(27.59) | |
心肾阴虚证[例(%)] |
6(10.00) |
5(8.62) | |
气阴两虚证[例(%)] |
12(20.00) |
15(25.86) | |
阳气虚衰证[例(%)] |
2(3.33) |
3(5.17) | |
ApoE基因表型 |
E2/2型[例(%)] |
3(5.00) |
2(3.45) |
E3/2型[例(%)] |
7(11.67) |
9(15.52) | |
E3/3型[例(%)] |
27(45. 00) |
29(50.00) | |
E2/4型[例(%)] |
5(8.33) |
3(5.17) | |
E3/4型[例(%)] |
10(16.67) |
7(12.07) | |
E4/4型[例(%)] |
8(13.33) |
8(13.79) | |
ApoE等位基因 |
ε2[例(%)] |
18(15.00) |
16(13.79) |
ε3[例(%)] |
71(59.17) |
74(63.79) | |
ε4[例(%)] |
31(25.83) |
26(22.42) |
|
气阴两虚 |
痰阻心脉 |
心血瘀阻 | ||||
治疗前 |
治疗后 |
治疗前 |
治疗后 |
治疗前 |
治疗后 | ||
治疗组(n=60) |
ε2 |
6.40±1.80 |
3.3±2.60* |
7.90±2.60 |
4.3±2.10*△ |
3.50±2.40 |
2.34±1.76* |
ε3 |
6.31±1.60 |
3.1±1.40* |
7.50±3.00 |
4.1±1.50*△ |
3.00±1.90 |
2.62±1.25* | |
ε4 |
7.58±2.10 |
3.6±1.15* |
9.80±3.30 |
4.6±2.30* |
3.30±1.90 |
2.80±1.26* | |
对照组(n=58) |
ε2 |
7.45±1.29 |
4.05±0.50* |
7.35±2.41 |
3.46±1.70* |
3.00±2.60 |
2.00±1.35* |
ε3 |
6.35±1.80 |
4.58±1.50* |
7.65±3.10 |
3.65±2.40* |
3.50±1.90 |
5.26±1.50* | |
ε4 |
6.50±2.10 |
3.8±2.00* |
9.60±2.40 |
5.3±2.00* |
3.60±1.50 |
2.53±1.26* |
TA的其他文章: